

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 February 2024 (01.02.2024)



(10) International Publication Number
WO 2024/025602 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 37/02 (2006.01)
A61P 21/04 (2006.01) C12N 15/00 (2006.01)

(21) International Application Number:

PCT/US2022/076691

(22) International Filing Date:

20 September 2022 (20.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/369,590 27 July 2022 (27.07.2022) US

(71) Applicant: **VIELA BIO, INC.** [US/US]; 1 Horizon Way,
Deerfield, Illinois 60015 (US).


(72) Inventors: **REES, William**; c/o Viela Bio, Inc., 1 Horizon
Way, Deerfield, Illinois 60015 (US). **SMITH, Michael**; c/
o Viela Bio, Inc., 1 Horizon Way, Deerfield, Illinois 60015
(US). **KATZ, Eliezer**; c/o Viela Bio, Inc., 1 Horizon Way,
Deerfield, Illinois 60015 (US).

(74) Agent: **BROWN, Fraser** et al.; Cooley LLP, 1299 Pennsylv-
ania Avenue NW, Suite 700, Washington, District of Co-
lumbia 20004 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

(54) Title: INEBILIZUMAB AND METHODS OF USING THE SAME FOR SUSTAINED B-CELL DEPLETION



ADCC, antibody-dependent cell-mediated cytotoxicity; F, phenylalanine; NK, natural killer; V, valine.

FIG.5A

(57) Abstract: Compositions and methods for using an Inebilizumab to treat autoimmune disease are disclosed herein. In particular the use of Inebilizumab to treat Neuromyelitis optica spectrum disorder are provided as well as exemplary therapeutic regimens.

[Continued on next page]

WO 2024/025602 A1

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*